

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

---

**SECTION 1. IDENTIFICATION**

Product identifier : Ivermectin / Abamectin Liquid Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Rua Coronel Bento Soares, 530  
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification in accordance with ABNT NBR 14725 Standard**

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin irritation : Category 2

Eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)  
single exposure (Oral)

Specific target organ toxicity - : Category 3  
single exposure

Specific target organ toxicity - : Category 2 (Central nervous system)  
repeated exposure

Short-term (acute) aquatic : Category 1  
hazard

Long-term (chronic) aquatic : Category 1  
hazard

**GHS label elements in accordance with ABNT NBR 14725 Standard**

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Hazard pictograms

:



Signal Word

: Danger

Hazard Statements

: H302 + H332 Harmful if swallowed or if inhaled.  
H315 Causes skin irritation.  
H319 Causes serious eye irritation.  
H335 May cause respiratory irritation.  
H360D May damage the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements

: **Prevention:**

P201 Obtain special instructions before use.  
P270 Do not eat, drink or smoke when using this product.  
P271 Use only outdoors or in a well-ventilated area.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.  
P302 + P352 IF ON SKIN: Wash with plenty of water.  
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.  
P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture

: Mixture

## Ivermectin / Abamectin Liquid Formulation

Version 7.1      Revision Date: 03.02.2025      SDS Number: 1210001-00026      Date of last issue: 28.09.2024  
 Date of first issue: 10.01.2017

**Components**

Chemical name	CAS-No.	Classification	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	Flam. Liq., 4 Acute Tox. (Oral), 5 Skin Irrit., 2 Eye Irrit., 2A Repr., 1B STOT SE, 3	$\geq 20$ -< 30
Ivermectin	70288-86-7	Acute Tox. (Oral), 2 Acute Tox. (Dermal), 3 STOT SE, (Oral)(Central nervous system) , 1 STOT RE, (Oral)(Central nervous system) , 1 Aquatic Acute, 1 Aquatic Chronic, 1	$\geq 1$ -< 2,5
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	Acute Tox. (Oral), 2 Acute Tox. (Inhalation), 1 Acute Tox. (Dermal), 3 Repr., 2 STOT RE, (Oral)(Central nervous system) , 1 Aquatic Acute, 1 Aquatic Chronic, 1	$\geq 1$ -< 2,5
(dl)-a-Tocopheryl acetate	7695-91-2		< 0,1

**SECTION 4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 If not breathing, give artificial respiration.  
 If breathing is difficult, give oxygen.  
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
 If easy to do, remove contact lens, if worn.  
 Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Most important symptoms and effects, both acute and delayed	:	Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. Harmful if swallowed or if inhaled. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO <sub>x</sub> )
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapors.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Keep in a cool, well-ventilated place.  
Store in accordance with the particular national regulations.

## Ivermectin / Abamectin Liquid Formulation

Version 7.1      Revision Date: 03.02.2025      SDS Number: 1210001-00026      Date of last issue: 28.09.2024  
 Date of first issue: 10.01.2017

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Self-reactive substances and mixtures  
 Organic peroxides  
 Explosives  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ivermectin	70288-86-7	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	150 µg/100 cm <sup>2</sup>	Internal
(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 µg/m <sup>3</sup> (OEB 1)	Internal

## Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of workday	100 mg/l	BR BEI
		5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

## Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Filter type	: recommended guidelines, use respiratory protection.
Hand protection	: Combined particulates and organic vapor type
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state	: liquid
Color	: light yellow
Odor	: characteristic
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: > 100 °C
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Relative density	:	No data available
Density	:	0,91 - 1,00 mg/l
Solubility(ies)	:	
Water solubility	:	insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Harmful if swallowed or if inhaled.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: 981,33 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 1,84 mg/l Exposure time: 4 h Test atmosphere: dust/mist



**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

---

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5.000 mg/kg  
Method: Calculation method

**Components:****N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4.150 mg/kg  
Method: OECD Test Guideline 401  
Remarks: The test was conducted equivalent or similar to guideline

Acute inhalation toxicity : LC50 (Rat): > 5,1 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Remarks: The test was conducted according to guideline

Acute dermal toxicity : LD50 (Rat): > 5.000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: The test was conducted equivalent or similar to guideline

**Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Acute oral toxicity : LD50 (Rat): 24 mg/kg  
LD50 (Mouse): 10 mg/kg  
LDLo (Monkey): 24 mg/kg  
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0,023 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

---

Acute dermal toxicity : LD50 (Rat): 330 mg/kg  
LD50 (Rabbit): 2.000 mg/kg

**(dl)-a-Tocopheryl acetate:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 3.000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : Skin irritation  
Remarks : The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species : Rabbit  
Result : No skin irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rabbit  
Result : No skin irritation

**(dl)-a-Tocopheryl acetate:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405  
Remarks : The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	:	Rabbit
Result	:	Mild eye irritation

**(dl)-a-Tocopheryl acetate:**

Species	:	Rabbit
Result	:	No eye irritation
Method	:	OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

**Ivermectin:**

Routes of exposure	:	Dermal
Species	:	Humans
Result	:	Does not cause skin sensitization.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Result	:	Not a skin sensitizer.

**(dl)-a-Tocopheryl acetate:**

Test Type	:	Draize Test
Routes of exposure	:	Skin contact
Species	:	Humans
Result	:	negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Method: OECD Test Guideline 471
		Result: negative

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

---

Remarks: The test was conducted according to guideline

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: The test was conducted according to guideline

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)

Method: OECD Test Guideline 482

Result: negative

Remarks: The test was conducted equivalent or similar to guideline

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: The test was conducted according to guideline

**Ivermectin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)

Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**(dl)-a-Tocopheryl acetate:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Method: OECD Test Guideline 473

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Method : OECD Test Guideline 451  
Result : negative  
Remarks : The test was conducted according to guideline

Species : Rat  
Application Route : Inhalation  
Exposure time : 2 Years  
Method : OECD Test Guideline 453  
Result : negative  
Remarks : The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species : Rat  
Application Route : Oral  
NOAEL : 1,5 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

Species : Mouse  
Application Route : Oral  
NOAEL : 2,0 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat  
Application Route : Oral  
Exposure time : 105 weeks  
Result : negative

Species : Mouse

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Application Route : Oral  
Exposure time : 93 weeks  
Result : negative

**(dl)-a-Tocopheryl acetate:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 104 weeks  
Result : negative

**Reproductive toxicity**

May damage the unborn child.

**Components:****N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 416  
Result: negative  
Remarks: The test was conducted according to guideline

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: positive  
Remarks: The test was conducted according to guideline

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: inhalation (vapor)  
Method: OECD Test Guideline 414  
Result: positive  
Remarks: The test was conducted equivalent or similar to guideline

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: positive  
Remarks: The test was conducted equivalent or similar to guideline

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**Ivermectin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

---

Fertility: NOAEL: 0,6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0,2 mg/kg body weight  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0,4 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected.  
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Early Embryonic Development: NOAEL: 0,12 mg/kg body weight  
Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight  
Developmental Toxicity: NOAEL: 0,2 mg/kg body weight  
Result: Cleft palate  
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Cleft palate, Teratogenic effects., Reduced embryonic survival

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Remarks: Adverse developmental effects were observed

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 1,6 mg/kg body weight  
Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**(dl)-a-Tocopheryl acetate:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**

May cause respiratory irritation.  
May cause damage to organs (Central nervous system) if swallowed.

**Components:****N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

**Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

**STOT-repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Routes of exposure : Ingestion  
Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.



## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

exposure.

**Repeated dose toxicity****Components:****N-Methyl-2-pyrrolidone:**

Species	: Rat, male
NOAEL	: 169 mg/kg
LOAEL	: 433 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Method	: OECD Test Guideline 408
Remarks	: The test was conducted according to guideline

Species	: Rat
NOAEL	: 0,5 mg/l
LOAEL	: 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 96 Days
Method	: OECD Test Guideline 413
Remarks	: The test was conducted according to guideline

Species	: Rabbit, male
NOAEL	: 826 mg/kg
LOAEL	: 1.653 mg/kg
Application Route	: Skin contact
Exposure time	: 20 Days
Method	: OECD Test Guideline 410
Remarks	: The test was conducted equivalent or similar to guideline

**Ivermectin:**

Species	: Dog
NOAEL	: 0,5 mg/kg
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Central nervous system
Symptoms	: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species	: Monkey
NOAEL	: 1,2 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 0,4 mg/kg
LOAEL	: 0,8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: spleen, Bone marrow, Kidney

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Species : Rat  
NOAEL : 1,5 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Target Organs : Central nervous system  
Symptoms : Tremors, ataxia

Species : Mouse  
NOAEL : 4,0 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Target Organs : Central nervous system  
Symptoms : Tremors, ataxia

Species : Dog  
NOAEL : 0,25 mg/kg  
LOAEL : 0,5 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Target Organs : Central nervous system  
Symptoms : Tremors, weight loss  
Remarks : mortality observed

Species : Monkey  
NOAEL : 1,0 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Central nervous system

**(dl)-a-Tocopheryl acetate:**

Species : Rat  
NOAEL : 500 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

**Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.  
Eye contact : Remarks: May irritate eyes.  
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

## SECTION 12. ECOLOGICAL INFORMATION

**Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

- |  |   |  |
|--|---|--|
| Toxicity to fish   | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l<br>Exposure time: 96 h  |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): > 1.000 mg/l<br>Exposure time: 24 h<br>Method: DIN 38412<br>Remarks: The test was conducted according to guideline                  |
| Toxicity to algae/aquatic plants                                       | : | ErC50 (Desmodesmus subspicatus (green algae)): 600,5 mg/l<br>Exposure time: 72 h<br><br>EC10 (Desmodesmus subspicatus (green algae)): 92,6 mg/l<br>Exposure time: 72 h |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 12,5 mg/l<br>Exposure time: 21 d<br>Method: OECD Test Guideline 211<br>Remarks: The test was conducted according to guideline       |
| Toxicity to microorganisms   | : | EC50 (activated sludge): > 600 mg/l<br>Exposure time: 30 min<br>Method: ISO 8192<br>Remarks: The test was conducted according to guideline                             |

**Ivermectin:**

- |   |   |  |
|---|---|--|
| Toxicity to fish                                    | : | LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l<br>Exposure time: 96 h<br><br>LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l<br>Exposure time: 96 h   |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0,000025 mg/l<br>Exposure time: 48 h  |
| Toxicity to algae/aquatic plants                    | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br><br>NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
| M-Factor (Acute aquatic toxicity)                   | : | 10.000   |
| M-Factor (Chronic aquatic toxicity)                 | : | 10.000   |

## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

toxicity)

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

- |  |   |
|--|---|
| <p>Toxicity to fish</p> <p>LC50 (Oncorhynchus mykiss (rainbow trout)): 3,2 µg/l<br/>Exposure time: 96 h</p> <p>LC50 (Lepomis macrochirus (Bluegill sunfish)): 9,6 µg/l<br/>Exposure time: 96 h</p> <p>LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l<br/>Exposure time: 96 h</p> <p>LC50 (Cyprinus carpio (Carp)): 42 µg/l<br/>Exposure time: 96 h</p> <p>LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l<br/>Exposure time: 96 h</p> | <p>Toxicity to daphnia and other aquatic invertebrates</p> <p>EC50 (Americamysis): 0,022 µg/l<br/>Exposure time: 96 h</p> <p>EC50 (Daphnia magna (Water flea)): 0,34 µg/l<br/>Exposure time: 48 h</p> |
| <p>Toxicity to algae/aquatic plants</p> <p>EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l<br/>Exposure time: 72 h</p>  |   |
| <p>M-Factor (Acute aquatic toxicity)</p> <p>Toxicity to fish (Chronic toxicity)</p> <p>NOEC (Pimephales promelas (fathead minnow)): 0,52 µg/l<br/>Exposure time: 32 d</p>  |   |
| <p>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</p> <p>NOEC (Daphnia magna (Water flea)): 0,03 µg/l<br/>Exposure time: 21 d</p> <p>NOEC (Mysidopsis bahia (opossum shrimp)): 0,0035 µg/l<br/>Exposure time: 28 d</p>   |   |
| <p>M-Factor (Chronic aquatic toxicity)</p> <p>Toxicity to microorganisms</p> <p>EC50: &gt; 1.000 mg/l<br/>Exposure time: 3 h<br/>Test Type: Respiration inhibition</p>   |   |
| <p><b>(dl)-a-Tocopheryl acetate:</b></p>   |   |
| <p>Toxicity to fish</p> <p>LC50 (Oncorhynchus mykiss (rainbow trout)): &gt; 100 mg/l<br/>Exposure time: 96 h<br/>Method: OECD Test Guideline 203</p>   |   |
| <p>Toxicity to daphnia and other aquatic invertebrates</p> <p>EC50 (Daphnia magna (Water flea)): &gt; 100 mg/l<br/>Exposure time: 48 h<br/>Method: OECD Test Guideline 202</p>   |   |
| <p>Toxicity to algae/aquatic</p> <p>ErC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 100</p>  |   |

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

plants	mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l Exposure time: 28 d
Toxicity to microorganisms	: EC50: > 927 mg/l Exposure time: 30 min Method: ISO 8192

**Persistence and degradability****Components:****N-Methyl-2-pyrrolidone:**

Biodegradability	: Result: Readily biodegradable. Biodegradation: 73 % Exposure time: 28 d Method: OECD Test Guideline 301C Remarks: The test was conducted according to guideline
------------------	---

**Ivermectin:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d
------------------	--

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Stability in water	: Hydrolysis: 50 %(< 12 h)
--------------------	----------------------------

**(dl)-a-Tocopheryl acetate:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 21,7 - 31 % Exposure time: 28 d Method: OECD Test Guideline 301C
------------------	--

**Bioaccumulative potential****Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water	: log Pow: -0,46 Method: OECD Test Guideline 107 Remarks: The test was conducted according to guideline
--	---

**Ivermectin:**

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3,22

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

**Mobility in soil****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3,6

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****ANTT**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)  
Class : 9  
Packing group : III  
Labels : 9  
Hazard Identification Number : 90

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

**Ivermectin / Abamectin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

**SECTION 16. OTHER INFORMATION**

Revision Date : 03.02.2025  
Date format : dd.mm.yyyy

**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)  
BR BEI : Brazil. NR7. Parameters for Biological Control of Occupational Exposure to Some Chemical Agents

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified



## Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.1	03.02.2025	1210001-00026	Date of first issue: 10.01.2017

---

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8